A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 19, 2014

Primary Completion Date

July 10, 2014

Study Completion Date

July 10, 2014

Conditions

AsthmaHealthy Subjects or Volunteers

Interventions

BIOLOGICAL

Tralokinumab 300 mg

Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.

Trial Locations (2)

Celerion, Lincoln

Research Site, Lincoln